Aliko Scientific announces settlement of a dispute involving its US subsidiary, which will receive USD 2 million

Paris, France – September 21, 2026 –7:45 am CEST – ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, announces that its wholly-owned US subsidiary has reached a settlement resolving an existing dispute, pursuant to which it will receive a payment of USD 2 million.

The related proceedings have been dismissed.

About ALIKO SCIENTIFIC (Ikonisys SA)

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology.

For more information, visit: www.alikoscientific.com

About IKONISYS

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

For more information, visit: www.ikonisys.com

About PARTNER INTERNATIONAL

Partner International is a global life sciences business development organization supporting pharmaceutical, biotechnology, medical technology and diagnostics companies in the identification and execution of strategic transactions and commercial partnerships. With more than 25 years of experience and a proprietary global network of more than 45,000 senior industry executives and decision-makers, Partner International supports clients across partnering, licensing, distribution, strategic alliances, M&A and other business development initiatives. Partner International operates internationally across North America, Europe and Asia, providing clients with senior-level business development resources and structured, targeted access to potential partners worldwide.

For more information, visit: partner-intl.com

About HOSPITEX

Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world’s most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics.

For more information, visit: www.hospitex.com